tively. For hypertensive patients treated with statins (≥ included trials) the standardized effect size of DSBP and DDBP was p = 0.33) and -0.12 (95%CI: -0.36 -1.1, p = 0.31), respectively. CONCLUSIONS: Despite some clinical disagreements, statin therapy in normotensive or hypertensive patients does not lead to reductions in systolic and diastolic blood pressure. Despite these results, however, the routine use of statins, even in patients with hypertension should be always considered due to the essential reduction of cardiovascular events.

PCV6 COMPARATIVE EFFECTIVENESS OF DIFFERENT DRUG-ELUTING CORONARY STENTS - A SYSTEMATIC REVIEW OF TAIWAN STUDIES
Yu T, Wang VC Center for Drug Evaluation, Taipei, Taiwan
OBJECTIVES: The first coronary drug-eluting stent gained its market approval in Europe 2002. Many different drug-eluting stents came to the market worldwide since then. In Taiwan, National Health Insurance has partially reimbursed drug-eluting stents since 2006. The number of claimed usage increased from 521 (2006) up to 14,311 (year 2010), and total claims reimbursement went up from NTD 15 million to 300 million. The impact to the NIH has been increasing. The aim of this study is to summarize the results of Taiwan drug-eluting stents studies for future researches.
METHODS: We systematically searched three bibliographic databases: EMBASE, PubMed and Taiwan National Central Library for studies utilizing Taiwan local data. In order to collect as many local studies as we can, no restrictions were applied on publication year, study type, disease, patients, intervention, comparator and outcomes. RESULTS: Among the 73 studies we identified in EMBASE and PubMed, only 11 studies met our predefined control trial criteria. The authors have evaluated the preventive outcome of phosphorylcholine-coated dexamethasone stent by observing restenosis rate. We then expanded our analysis scopes to controlled trials, and additional 26 studies were identified and 3 studies matched our research question. Their topics were about “1 year follow-up after PCI with Titan versus TAXUS stents”, “Gender differences in patients undergoing coronary stenting” and “the effects of starting statin therapy before PCI with drug-eluting stents”. On the other part of our research at Taiwan National Central Library, there was no paper matched our including criteria. Most of the papers included there were coronary stents design related articles. CONCLUSIONS: Based on systematical research results, we only found one randomized control trial fully used Taiwan local data. Lack of comparative effectiveness on local stents usage could pose a problem when considering evidence-based decision making.

PCV7 IMPLEMENTING AND EVALUATING PHARMACIST-MANAGED WARFARIN SERVICE IN INPATIENT AND OUTPATIENT SETTING IN TAIWAN
Wang YP1, Tseng TH2, Huang SY2,3
1Taipei Medical University – Shuang Ho Hospital, New Taipei City, Taiwan, 2Taipei Medical University – Shuang Ho Hospital, New Taipei City, Taiwan, 3Taipei Medical University – Shuang Ho Hospital, New Taipei City, Taiwan, Taiwan
OBJECTIVES: To identify approaches and to evaluate efficacy of implementing an electronic service program involving pharmacists. METHODS: The pharmacy department worked with the medical staff to establish a warfarin service, including guidelines approval. Pharmacist-managed warfarin service was provided in neurology ward or for patients who were referred from physicians, and others remained standard care of anticoagulants. Data was collected for 3 months after the pharmacist-managed warfarin service program involving pharmacists. CONCLUSIONS: Based on systematically research results, we only found one randomized control trial fully used Taiwan local data. Lack of comparative effectiveness on local stents usage could pose a problem when considering evidence-based decision making.

PCV8 EVALUATION OF EFFICACY AND SAFETY OF ANTIHYPERTENSIVE DRUGS ON THE REIMBURSEMENT LIST FOR DELISTING POLICY IN KOREA
Kim E1, Lee HY1, Kim CH2, Lee SM3, Lee YS2, Ohn HS4, Choi SI5,6
1Seoul National University, Seoul, South Korea, 2Medical University of South Carolina, Charleston, South Carolina, USA, 3Korea University, Seoul, South Korea, 4Inje Institute of Advanced Studies(IAIS), Seoul, South Korea, 5College of Pharmacy, Su-Won, South Korea, 6Korea University, Suwon, South Korea, Seoul, South Korea, Seoul, South Korea, 7Korea University, Seoul, South Korea, Yong-In, Chung, South Korea
OBJECTIVES: To develop evaluation criteria comparing efficacy and safety of anti-hypertensive drugs and to perform comparative analysis based on the developed criteria on the pre-existing anti-hypertensive drugs on reimbursement list in Korea. METHODS: A total of 1226 items with 131 ingredients were categorized into 5 classes: Diuretics, β-blocker, Calcium channel blocker, Angiotensin—converting enzyme inhibitors, Angiotensin-Receptor-blocker. Proxy and final outcomes evaluating efficacy of antihypertensive drugs were determined based on previous studies and opinion of experts. For proxy outcomes, Systolic blood pressure and Diastolic blood pressure were used in all-case mortality, non-fatal myocardial infarction, non-fatal stroke, cardiovascular morbidity, and cardiovascular mortality were used as final outcomes. Proper criteria evaluating safety are impossible to choose because symptoms and frequency of adverse event varies depending on classes. Systematic review literatures in Korea and other countries were searched using databases such as PubMed, Cochrane, Embase, Center for Review & Dissemination, KMBase, and KoreaMed. In addition, 6 assessment reports from overseas health technology institutions and opinions of clinical experts were referenced. Finally, 7 literatures using proxy outcomes and 8 literatures using final outcomes were reviewed in previous literatures. Additional statistical analysis was not performed. RESULTS: On in-depth examination, there was no profound evidence depicting difference in proxy and final outcomes among classes and among ingredients in the same class. Results of 6 overviews technical reports aforementioned were the same as the ones of SR literatures. Opinions of clinical experts confirmed the findings of in-depth examination in proxy outcomes adding that efficacy in final outcomes can be different depending on the co-morbidity status. CONCLUSIONS: It was not proven that a particular class or ingredient is superior to others. Therefore, it is expected that reimbursement list is reorganized based on this result, improvement of public health and saving of health insurance finance is feasible without depriving the prescription rights of clinicians.

PCV9 META-ANALYSIS OF THE EFFICACY AND SAFETY OF STEVIOSE (FROM STEVIA REBAUDIANA BERTONI) IN BLOOD PRESSURE CONTROL IN PATIENTS WITH HYPERTENSION
Poolaop N, Yongmesa T, Cheunchom C, Rachawat P, Boonsong R
Department of Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand
OBJECTIVES: Stevioside is a major constituent of the plant Stevia rebaudiana Bertoni (SRB). Its beneficial effect on human blood pressure has been demonstrated in many studies, with no significant adverse effects being reported. This meta-analysis was aimed to evaluate the efficacy and safety of stevioside against placebo in blood pressure control in hypertensive patients. METHODS: A systematic search for relevant studies was performed of the PubMed, ScienceDirect, Cochrane Library and Wiley Online Library databases from their respective inception until February 2012. The reference list of the retrieved studies was also examined. Stevia rebaudiana Bertoni, stevioside, hypertension and randomized controlled trial were used as searching keywords. The studies were included if they: 1. were randomized controlled trials (RCTs) comparing stevioside from SRB with placebo in hypertensive patients; 2. reported on systolic blood pressure (SBP) and diastolic blood pressure (DBP); and 3. were published in English. Data were pooled using the inverse variance-weighted method and statistical analyses were performed using the Review Manager (RevMan) version 5.1.4. RESULTS: Three RCTs involving altogether 280 patients were included in the analysis. Stevioside was found to be effective in reducing SBP, with no significant effect on DBP, compared to placebo. The pooled mean differences in SBP and DBP were -10.43 mmHg (95% CI: -12.15 to -8.72 mmHg, p < 0.01) and -6.77 mmHg (95% CI: -13.23 to -0.30 mmHg, p = 0.05), respectively. There was no significant difference in adverse events expressed in the two groups (OR: 1.32, 95% CI: 0.61 to 2.68). CONCLUSIONS: Our findings suggest the efficacy of stevioside in reducing SBP but not DBP in hypertensive patients. Additionally, stevioside was shown to produce no significant adverse events in this group of patients.

PCV10 ANALYSIS OF CONSUMPTION OF ACE INHIBITORS FUNDED BY REPUBLIC OF KOREA 4TH HEALTH INSURANCE OF SERBIA IN 2009
Tomic Z1, Sabo A2, Milijaševic B1, Tomic Z1, Sabo A1, Vukmirovic S1,2
1Faculty of Medicine, University of Novi Sad, Novi Sad, Vojsidina, Serbia and Montenegro, 2Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia and Montenegro
OBJECTIVES: Cardiovascular diseases are the most frequent cause of morbidity and mortality in many countries. That explains why medications for the treatment of cardiovascular diseases are group of drugs with largest consumption, and ACE inhibitors take a large part in the consumption. The aim of this study was to analyze the consumption of prescribed ACE inhibitors, in Serbia during year 2009.
METHODS: The data about the use of ACE inhibitors were obtained from the Republic of Public Health Insurance of the Serbia (RFZO. RESULTS: Total consumption of ACE inhibitors in year 2009 was 176,29 DDD and total financial outlay was 59.772.897,11 €. The largest use of ACE inhibitors was for enalapril (78,32 DDD), follow by fosinopril (20,09 DDD), ramipril (19,11 DDD) and cilazapril (14,19 DDD). The volume of consumption RFZO would save about 9.500.000,00 €.

PCV11 USE OF ANTI-INFECTIVES FOR SYSTEMIC ADMINISTRATION IN SERBIA IN 2010
Milijašević B1, Tomic Z2, Sabo A1, Vukmirovic S1
1Faculty of Medicine, University of Novi Sad, Novi Sad, Vojsidina, Serbia and Montenegro, 2Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia and Montenegro
CONCLUSIONS: It was not proven that a particular class or ingredient is superior to others. Therefore, it is expected that reimbursement list is reorganized based on this result, improvement of public health and saving of health insurance finance is feasible without depriving the prescription rights of clinicians.